Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EMPAGLIFLOZIN AND LINAGLIPTIN vs ALESSE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormones (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon levels.
Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin-releasing hormone (Gn RH) secretion from the hypothalamus, inhibiting pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing ovulation. Additionally, it thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Reduce risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease
Prevention of pregnancy,Treatment of moderate acne vulgaris (in women ≥15 years who have achieved menarche and desire contraception),Contraception in women with heavy menstrual bleeding (off-label)
10 mg empagliflozin / 5 mg linagliptin orally once daily
One tablet (ethinyl estradiol 20 mcg, levonorgestrel 0.1 mg) orally once daily at the same time each day for 21 days, followed by 7 days of placebo. For initiation, start on the first day of menstrual period or first Sunday after onset of menses.
Empagliflozin: terminal half-life ~12.4 hours, allowing once-daily dosing. Linagliptin: terminal half-life ~113-131 hours due to saturable binding to DPP-4, enabling once-daily dosing despite short plasma half-life.
Levonorgestrel: terminal half-life ~17-20 hours (range 11-25 hr). Ethinyl estradiol: biphasic; terminal half-life ~13-27 hours (mean ~17 hr). Clinical context: steady-state achieved within 5-7 days. The half-life supports once-daily dosing with at least 24-hour contraceptive coverage.
Empagliflozin: primarily glucuronidation by UGT2B7, UGT1A3, UGT1A8, and UGT1A9. Linagliptin: primarily enterohepatic recirculation with minimal hepatic metabolism; metabolized by CYP3A4 to a minor extent.
Ethinyl estradiol is primarily metabolized by CYP3A4 and undergoes conjugation (glucuronidation and sulfation). Levonorgestrel is metabolized by CYP3A4 and reduction, with conjugation to glucuronide and sulfate conjugates.
Empagliflozin: 54% excreted unchanged in urine (renal), 41% in feces (biliary/fecal). Linagliptin: 80% excreted unchanged in feces via enterohepatic circulation, <5% in urine.
Renal: ethinyl estradiol (UE2) and levonorgestrel (LNG) metabolites primarily excreted in urine (UE2: ~40% as sulfate and glucuronide conjugates; LNG: ~25% as glucuronides). Fecal/biliary: ~40% (UE2) and ~45% (LNG) eliminated in feces via bile. Unchanged drug excretion is negligible.
Empagliflozin: 86.2% bound primarily to plasma proteins (albumin). Linagliptin: 70-89% bound; concentration-dependent, mainly to albumin.
Levonorgestrel: 97-99% bound to albumin and sex hormone-binding globulin (SHBG). Ethinyl estradiol: 98-99% bound, primarily to albumin (98.5%), with minor binding to SHBG. Free fractions: LNG ~1%, UE2 ~1.0-1.5%.
Empagliflozin: Vd ~38 L (0.5-0.6 L/kg), reflecting moderate tissue distribution. Linagliptin: Vd ~1,040 L (15 L/kg), indicating extensive tissue binding (e.g., DPP-4 enzyme).
Levonorgestrel: Vd ~1.8 L/kg (range 1.5-2.0 L/kg). Ethinyl estradiol: Vd ~2.5-3.5 L/kg (mean ~2.9 L/kg). Indicates extensive tissue distribution, including target organs (ovaries, endometrium, breast). Not clinically adjusted for obesity.
Empagliflozin: oral bioavailability ~78% in therapeutic range, decreased with high-fat meal; no dose adjustment. Linagliptin: oral bioavailability ~30% due to presystemic metabolism; food decreases Cmax but not AUC.
Oral: levonorgestrel ~95-100% (highly bioavailable). Ethinyl estradiol ~45-55% (first-pass metabolism reduces bioavailability; interindividual variability due to gut wall and hepatic conjugation). Both are prodrugs requiring hydrolysis for activity.
e GFR ≥45 m L/min/1.73m2: no adjustment. e GFR 30-44: contraindicated (empagliflozin labeled for use, but renal efficacy not established; linagliptin no adjustment). e GFR <30: contraindicated (empagliflozin); linagliptin no adjustment but caution. Empagliflozin not recommended if on dialysis.
No specific GFR-based dose adjustments are recommended; however, use with caution in patients with renal impairment due to potential fluid retention and hypertension.
Child-Pugh A, B, C: no adjustment required for empagliflozin or linagliptin. However, experience in severe hepatic impairment is limited.
Contraindicated in patients with severe hepatic disease (Child-Pugh class C) or active liver disease. In mild to moderate impairment (Child-Pugh A or B), use only if benefits outweigh risks; no specific dose reduction guidelines are available.
Safety and efficacy not established in pediatric patients under 18 years.
Approved for postmenarchal adolescents; same dosing as adults: one tablet orally once daily for 21 days followed by 7 days of placebo. No weight-based adjustments are recommended.
No specific dose adjustment based on age alone. Monitor renal function regularly; consider risk of volume depletion and hypotension with empagliflozin in elderly patients.
Not indicated for use in postmenopausal women; no specific geriatric dosing adjustments are necessary if used off-label, but consider increased risk of thrombotic events in older women.
None.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. The risk increases with age, particularly in women over 35 years, and with heavy smoking (≥15 cigarettes per day). Women over 35 who smoke should not use this medication.
Pancreatitis (reported with DPP-4 inhibitors),Heart failure (reported with DPP-4 inhibitors),Hypoglycemia (especially when used with insulin or sulfonylureas),Genital mycotic infections,Urinary tract infections,Volume depletion/hypotension (especially in elderly, renal impairment, or diuretic use),Acute kidney injury,Ketoacidosis (including euglycemic ketoacidosis),Lower limb amputation (associated with SGLT2 inhibitors),Necrotizing fasciitis of the perineum (Fournier's gangrene),Severe and disabling arthralgia (reported with DPP-4 inhibitors)
Increased risk of thromboembolic disorders (venous and arterial),Cigarette smoking increases risk of cardiovascular events, especially in women over 35,Hepatic neoplasia (benign and malignant),Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache/migraine,Depression,Uterine bleeding irregularities,Ocular lesions (e.g., retinal thrombosis),Carcinoma of the breast and reproductive organs (close monitoring in current or history of breast cancer)
Hypersensitivity to empagliflozin, linagliptin, or any component,History of serious hypersensitivity reaction (e.g., anaphylaxis, angioedema) to either component,Type 1 diabetes mellitus,Diabetic ketoacidosis,Severe renal impairment (e GFR < 30 m L/min/1.73 m2),End-stage renal disease or dialysis
Breast cancer (current or history),Carcinoma of the endometrium or other estrogen-dependent neoplasia,Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Valvular heart disease with complications,Severe hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known or suspected pregnancy,Active liver disease or impaired liver function,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component,Cigarette smoking in women over 35 years of age
No significant food interactions. Acutely reduce alcohol consumption due to possible increased risk of ketoacidosis.
No specific food restrictions. Grapefruit juice may slightly increase ethinyl estradiol levels but not clinically significant. High-fat meals do not affect absorption. Avoid excessive alcohol as it may impair compliance.
Empagliflozin: Limited human data; animal studies show renal toxicity in developing kidneys. Risk cannot be excluded. Linagliptin: No evidence of teratogenicity in animal studies; limited human data. Both drugs are not recommended during pregnancy, especially in the second and third trimesters due to potential fetal renal effects.
Pregnancy category X. Use contraindicated in pregnancy. First trimester exposure associated with cardiovascular defects (e.g., VSD), neural tube defects, and cleft lip/palate. Second and third trimester exposure may cause fetal adrenal suppression, hepatic dysfunction, and virilization of female genitalia due to progestin component (levonorgestrel). Increased risk of ectopic pregnancy if conception occurs during use.
Empagliflozin: Unknown if excreted in human milk; risk to infant not excluded. Linagliptin: Excreted in rat milk; unknown in humans. M/P ratio not available. Breastfeeding is not recommended during therapy.
Excreted in breast milk. Levonorgestrel M/P ratio approximately 0.3–0.4. Small amounts of ethinyl estradiol present. May reduce milk production and quality due to estrogen component. Use only if benefit outweighs risk; consider alternative contraception. American Academy of Pediatrics considers it compatible with nursing.
No established dose changes for pregnancy; pharmacokinetic changes in pregnancy (increased renal clearance, volume of distribution) may alter drug exposure, but insufficient data to recommend adjustments. Therapy should be discontinued during pregnancy due to potential risks.
Contraindicated. No dose adjustments apply as drug must be discontinued immediately if pregnancy suspected or confirmed. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) not relevant due to contraindication.
Empagliflozin/linagliptin is a fixed-dose combination for type 2 diabetes. Assess renal function before initiation; empagliflozin is not recommended if e GFR <30 m L/min/1.73 m². Monitor for signs of ketoacidosis, even with normal glucose (euglycemic DKA). Linagliptin requires no dose adjustment for renal impairment. Use caution with loop diuretics due to volume depletion risk. Discontinue at time of surgery or during acute illness.
ALESSE is a combined oral contraceptive (COC) containing ethinyl estradiol (20 mcg) and levonorgestrel (100 mcg). It is indicated for contraception and treatment of acne vulgaris in women aged ≥14. Monitor for thromboembolic events, especially in smokers >35 years. Assess for contraindications including migraines with aura, hypertension, and history of DVT/PE. Advise use of backup contraception if a pill is missed. Start on first day of menses or first Sunday after onset. Check BP at baseline and annually. Counsel on increased risk of VTE, especially in first year.
Take once daily with or without food, preferably in the morning.,Stay adequately hydrated to prevent dehydration.,Report symptoms of genital yeast infections, urinary tract infections, or ketoacidosis (nausea, vomiting, abdominal pain, confusion, unusual fatigue).,Monitor blood glucose regularly.,Do not use during pregnancy or breastfeeding.,Inform healthcare providers of all medications, especially diuretics or insulin.,Seek immediate medical attention for difficulty breathing or swelling of face/lips/tongue.
Take one pill daily at the same time each day, even if you do not have sex.,Missed pill instructions: if late by <12 hours, take it as soon as remembered and continue schedule. If >12 hours, take missed pill (even if means taking two in one day) and use backup contraception for 7 days.,Possible side effects: nausea, breast tenderness, headache, breakthrough bleeding, especially in first 3 months.,Seek emergency care for signs of blood clot: leg pain/swelling, sudden chest pain, shortness of breath, severe headache, vision changes.,Do not smoke while on ALESSE, especially if over age 35, as it increases risk of serious cardiovascular events.,Inform your healthcare provider of all medications and supplements you take, as some (e.g., rifampin, anticonvulsants, St. John's wort) may reduce effectiveness.
"Empagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces renal glucose reabsorption, leading to decreased blood glucose levels. Rosoxacin, a quinolone antibiotic, may enhance the hypoglycemic effects of empagliflozin by potentiating insulin secretion or improving insulin sensitivity, which could increase the risk of hypoglycemic episodes, especially in patients with diabetes mellitus."
"Quinethazone, a thiazide-like diuretic, reduces intravascular volume and may blunt the osmotic diuretic effect of empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, thereby decreasing empagliflozin's efficacy in lowering blood glucose. This interaction is mediated through volume contraction leading to reduced renal perfusion and diminished glucose excretion. Clinically, patients may experience higher-than-expected blood glucose levels, potentially compromising glycemic control."
"Concomitant use of lisinopril, an angiotensin-converting enzyme inhibitor, and empagliflozin, a sodium-glucose cotransporter-2 inhibitor, may enhance the risk of hypotension, acute kidney injury, and hyperkalemia. Lisinopril reduces angiotensin II-mediated vasoconstriction and aldosterone secretion, which can be compounded by empagliflozin-induced volume depletion and osmotic diuresis. This interaction is particularly concerning in patients with renal impairment or those on other medications affecting the renin-angiotensin-aldosterone system."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EMPAGLIFLOZIN AND LINAGLIPTIN vs ALESSE, answered by our medical review team.
EMPAGLIFLOZIN AND LINAGLIPTIN is a DPP-4 Inhibitor that works by Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormones (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon levels.. ALESSE is a Estrogen/Progestin Combination Contraceptive that works by Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin-releasing hormone (Gn RH) secretion from the hypothalamus, inhibiting pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing ovulation. Additionally, it thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EMPAGLIFLOZIN AND LINAGLIPTIN and ALESSE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EMPAGLIFLOZIN AND LINAGLIPTIN is: 10 mg empagliflozin / 5 mg linagliptin orally once daily. The standard adult dose of ALESSE is: One tablet (ethinyl estradiol 20 mcg, levonorgestrel 0.1 mg) orally once daily at the same time each day for 21 days, followed by 7 days of placebo. For initiation, start on the first day of menstrual period or first Sunday after onset of menses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EMPAGLIFLOZIN AND LINAGLIPTIN and ALESSE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EMPAGLIFLOZIN AND LINAGLIPTIN is classified as Category A/B. Empagliflozin: Limited human data; animal studies show renal toxicity in developing kidneys. Risk cannot be excluded. Linagliptin: No evidence of teratogenicity in animal studies; . ALESSE is classified as Category C. Pregnancy category X. Use contraindicated in pregnancy. First trimester exposure associated with cardiovascular defects (e.g., VSD), neural tube defects, and cleft lip/palate. Seco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.